The FDA decision on Shire plc’s (SHPG) investigational treatment Lanadelumab is expected to be announced on August 26, 2018.The Company is seeking approval of Lanadelumab for the prevention of angioedema attacks in patients 12 years and older with the rare, genetic disorder, hereditary angioedema (HAE).Lanadelumab is formulated for subcutaneous administration, and has a half-life of approximately 14 days in patients with HAE.Analysts estimate that annual peak sales of Lanadelumab may reach up to $2 billion.In May, Shire agreed to be acquired by Japanese drugmaker Takeda Pharmaceutical for $62 billion, representing the biggest deal of the year so far.SHPG closed Wednesday’s trading (Jul 25) at $172.37, down 0.21%.